# Protocol Review and Monitoring System

> **NIH NIH P30** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2022 · $218,414

## Abstract

PROJECT SUMMARY/ABSTRACT (PROTOCOL REVIEW AND MONITORING SYSTEM)
The primary responsibility for the Protocol Review and Monitoring System (PRMS) rests with the University of
Michigan Comprehensive Cancer Center (UMCCC) Protocol Review Committee (PRC). The PRC is aided in its
pursuit of the PRMS Specific Aims by the Clinical Research Teams (CRTs) and the Scientific Progress Review
Subcommittee of the PRC (SPRS-PRC), which have specific, non-overlapping, and well-defined roles. The PRC,
which is comprised of experts in clinical research from diverse disciplines, provides independent peer review of
the scientific merit and feasibility of new cancer-related clinical protocols. It also monitors the scientific progress
of activated protocols to ensure that they continue to be of high scientific merit and priority, support the UMCCC
research mission, and achieve accrual goals in a realistic timeframe. By providing this level of exceptional peer-
review oversight of cancer clinical research at University of Michigan (U-M), the PRC helps to ensure that
UMCCC conducts high quality protocols that are scientifically impactful, realize their accrual targets, and utilize
UMCCC resources wisely (e.g., shared resources, UMCCC funds, and the Oncology Clinical Trials Support Unit
(O-CTSU)). The CRTs are disease- and domain-oriented groups in the UMCCC that serve as the nidus for
patient-oriented research. The teams are composed of multidisciplinary physicians, translational cancer research
scientists, advanced practice providers, nurses, geneticists, clinical research coordinators, data managers,
regulatory specialists, patient advocates, and others involved in the performance of clinical cancer research.
CRTs are led by mid-career and senior clinical investigators who have an academic primary focus on clinical
research, have significant experience as principal investigators on interventional cancer clinical trials (with
particular emphasis on investigator initiated trials, or IITs), and see patients in the clinics associated with their
respective disease team. The CRTs are charged with reviewing and prioritizing proposed cancer clinical trials
within their respective disease/domain that arise from the scientific themes in the CC Programs and elsewhere,
both to ensure scientific merit, and to increase the chances of success in implementation.

## Key facts

- **NIH application ID:** 10438640
- **Project number:** 5P30CA046592-33
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** Gregory Peter Kalemkerian
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $218,414
- **Award type:** 5
- **Project period:** 1997-06-01 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10438640

## Citation

> US National Institutes of Health, RePORTER application 10438640, Protocol Review and Monitoring System (5P30CA046592-33). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10438640. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*